Browsing by Author "Ridruejo, Ezequiel."
Now showing items 1-14 of 14
-
An Update on Hepatocellular Carcinoma in Chronic Kidney Disease
Ridruejo, Ezequiel.; Fabrizi, Fabrizio.; Cerutti, Roberta.; Et al. (MDPI [Commercial Publisher], 2021-07)Abstract Chronic kidney disease is a major public health issue globally and the risk of cancer (including HCC) is greater in patients on long-term dialysis and kidney transplant compared with the general population. ... -
Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma
Piñero, Federico.; Tisi Baña, Matías.; Ridruejo, Ezequiel.; Et al. (Elsevier, 2020-10)Abstract The A.A.E.E.H has developed this guideline for the best care of patients with hepatocellular carcinoma (HCC) from Argentina. It was done from May 2018 to March 2020. Specific clinical research questions were ... -
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection
Mendizabal, Manuel.; Piñero, Federico.; Ridruejo, Ezequiel. (Springer, 2021-11)Abstract Introduction and objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized ... -
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
Mendizabal, Manuel.; Piñero, Federico.; Ridruejo, Ezequiel.; Et al. (Elsevier, 2020-10)Abstract Background & aims: Little is known about how a sustained virologic response (SVR) to treatment of hepatitis C virus infection with direct-acting antivirals (DAAs) affects patient mortality and development of new ... -
Editorial: biomarkers in HBV and prediction of treatment response
Ridruejo, Ezequiel. (Wiley, 2021-01)Hepatitis B cure is clinically defined as persistently undetectable HBsAg and hepatitis B virus (HBV) DNA in serum, with or without seroconversion to hepatitis B surface antibody (anti-HBs). ... -
Hepatitis B virus vaccine and chronic kidney disease. The advances
Ridruejo, Ezequiel.; Fabrizi, Fabrizio.; Cerutti, Roberta.; Et al. (Sociedad española de nefrología, 2021-03)Abstract Background: Hepatitis B is an important agent of liver disease in patients with chronic kidney disease and chronic HBV infection promotes the development of CKD in the adult general population. Patients with CKD ... -
Hepatitis C virus infection in Argentina: Burden of chronic disease.
Ridruejo, Ezequiel.; Bessone, Fernando.; Daruich, Jorge.; Estes, Chris.; Gadano, Adrián.; Razavi, Homie.; Villamil, Federico.; Silva, Marcelo. (Baishideng Publishing Group, 2016-05-28)AIM: To estimate the progression of the hepatitis C virus (HCV) epidemic and measure the burden of HCV-related morbidity and mortality. METHODS: Age- and gender-defined cohorts were used to follow the viremic population ... -
Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges
Piñero, Federico.; Poniachk, Jaime.; Ridruejo, Ezequiel.; Silva, Marcelo. (Baishideng Publishing Group, 2018-10-07)Abstract Latin America, a region with a population greater than 600000000 individuals, is well known due to its wide geographic, socio-cultural and economic heterogeneity. Access to health care remains as the main barrier ... -
Hepatotoxicity Induced by Coxibs: How Concerned Should We Be?
Bessone, Fernando.; Hernandez, Nelia.; Roma, Marcelo.; Ridruejo, Ezequiel.; Mendizabal, Manuel.; et al. (Taylor & Francis, 2016-08-26)Introduction: The selective inhibitors of COX-2, coxibs, are nonsteroidal anti-inflammatory drugs (NSAIDs) that have much better gastrointestinal safety profile as compared with non-selective NSAIDs. In this review, we ... -
Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission
Mendizabal, Manuel.; Piñero, Federico.; Ridruejo, Ezequiel.; Et al. (Elsevier, 2021-03)Abstract Introduction & objectives: The independent effect of liver biochemistries as a prognostic factor in patients with COVID-19 has not been completely addressed. We aimed to evaluate the prognostic value of abnormal ... -
Reply
Mendizabal, Manuel.; Piñero, Federico.; Ridruejo, Ezequiel. (Elsevier, 2021-03) -
Simplified treatment of hepatitis C: another strategy to overcome the barriers to its elimination
Mendizabal, Manuel.; Silva, Marcelo.; Ridruejo, Ezequiel. (Medicina Buenos Aires, 2021-01)Abstract in English, Spanish The clinical management of hepatitis C virus (HCV) infection presents several challenges today. WHO's goal is to eliminate it by 2030. It is an ambitious goal and difficult to meet given the ... -
The liver in times of COVID-19: What hepatologists should know
Ridruejo, Ezequiel.; Soza, Alejandro (Elsevier, 2020-07)Abstract The ongoing pandemic of coronavirus disease 2019 (COVID-19) pandemic poses a serious threat to healthcare systems globally. Information regarding how the infection affects the liver and relevance of pre-existing ... -
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero, Federico.; Mendizabal, Manuel.; Ridruejo, Ezequiel.; Herz, Fernando.; Ameigeiras, Beatriz.; Anders, Margarita.; Schinoni, María.; et al. (Wiley, 2019-01-13)Abstract Background & Aims: Data from Europe and North America have been published re‐ garding the risk of developing hepatocellular carcinoma (HCC) after treatment with direct antiviral agents (DAA). We proposed to ...